当前位置： SCI文献检索 > Journal of Biopharmaceutical Statistics期刊下所有文献 > Statistical inference following sample size adjustment based on the 50%-conditional-power principle.

Statistical inference following sample size adjustment based on the 50%-conditional-power principle.

Abstract：

:Sample size adjustment at an interim analysis can mitigate the risk of failing to meet the study objective due to lower-than-expected treatment effect. Without modification to the conventional statistical methods, the type I error rate will be inflated, primarily caused by increasing sample size when the interim observed treatment effect is close to null or no treatment effect. Modifications to the conventional statistical methods, such as changing critical values or using weighted test statistics, have been proposed to address primarily such a scenario at the cost of flexibility or interpretability. In reality, increasing sample size when interim results indicate no or very small treatment effect could unnecessarily waste limited resource on an ineffective drug candidate. Such considerations lead to the recently increased interest in sample size adjustment based on promising interim results. The 50% conditional power principle allows sample size increase only when the unblinded interim results are promising or the conditional power is greater than 50%. The conventional unweighted test statistics and critical values can be used without inflation of type I error rate. In this paper, statistical inference following such a design is assessed. As shown in the numerical study, the bias of the conventional maximum likelihood estimate (MLE) and coverage error of its conventional confidence interval are generally small following sample size adjustment. We recommend use of conventional, MLE-based statistical inference when applying the 50% conditional power principle for sample size adjustment. In such a way, consistent statistics will be used in both hypothesis test and statistical inference.

journal_name

J Biopharm Stat

journal_title

Journal of biopharmaceutical statistics

authors

Chen YHJ,Yuan SS,Li X

doi

10.1080/10543406.2017.1372766

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

575-587

issue

3

eissn

1054-3406

issn

1520-5711

journal_volume

28

pub_type

杂志文章

相关文献

Journal of Biopharmaceutical Statistics文献大全
  • Statistical innovations in the medical device world sparked by the FDA.

    abstract：:The world of medical devices while highly diverse is extremely innovative, and this facilitates the adoption of innovative statistical techniques. Statisticians in the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) have provided leadership in implementing statistical innova...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2015.1092037

    authors： Campbell G,Yue LQ

    更新日期：2016-01-01 00:00:00

  • A global model to define the behavior of partial agonists (bell-shaped dose-response inducers) in pharmacological evaluation of activity in the presence of the full agonist.

    abstract：:The dose-response models for full agonists and for a particular type of partial agonist can be described by sigmoidal curves and bell-shaped curves, respectively. The methods currently used to evaluate the interaction of a full agonist and a partial agonist require a large number of experimental units and base their a...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409808835266

    authors： Ghosh K,Shen ES,Arey BJ,López FJ

    更新日期：1998-11-01 00:00:00

  • On sample size determination in multi-armed confirmatory adaptive designs.

    abstract：:An important application of confirmatory adaptive designs is the data-driven selection of treatment arms in multi-armed trials. A general methodology for adaptive designs is based on the combination testing principle. Using this principle, selection of treatment arms in multi-armed designs, recalculation of sample siz...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2011.551336

    authors： Wassmer G

    更新日期：2011-07-01 00:00:00

  • Innovative Thinking on Endpoint Selection in Clinical Trials.

    abstract：:In clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the t...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2019.1657140

    authors： Chow SC,Huang Z

    更新日期：2019-01-01 00:00:00

  • A model-based approach to estimate the AIDS-free time distribution in homosexual men using longitudinal data.

    abstract：:A model-based approach is developed to estimate the distribution of time from seroconversion to diagnosis with acquired immunodeficiency syndrome (AIDS) as a function of selected time-dependent covariates. The approach is applied to longitudinal data collected over 4 years of follow-up from 450 men seropositive for th...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 临床试验,杂志文章

    doi：10.1080/10543409408835078

    authors： Dunlop DD,Tamhane AC,Chmiel JS,Phair JP

    更新日期：1994-07-01 00:00:00

  • Designing studies to find early signals of efficacy.

    abstract：:We introduce the idea of a design to detect signals of efficacy in early phase clinical trials. Such a design features three possible decisions: to kill the compound; to continue with staged development; or to continue with accelerated development of the compound. We describe how such studies improve the trade-off bet...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2011.570466

    authors： Brown MJ,Chuang-Stein C,Kirby S

    更新日期：2012-01-01 00:00:00

  • Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

    abstract：:I review the designs available for Phase I dose-finding studies of chemotherapeutic agents in cancer patients. The designs are based on the assumption that both efficacy and toxicity increase with dose, and thus attempt to minimize the number of patients treated at low doses, and also to minimize the chance that patie...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543400600860295

    authors： Potter DM

    更新日期：2006-01-01 00:00:00

  • Simple methods for determination of the release limits for drug products.

    abstract：:The potency of a batch of drug product needs to meet a release limits at the time of release so that the potency at the end of shelf life remains above the lower registration limit (LRL). This article discusses two methods which determine the release limits such that the chance to fail LRL at the end of shelf life of ...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409808835225

    authors： Wei GC

    更新日期：1998-03-01 00:00:00

  • Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.

    abstract：:Large sample size imbalance is not uncommon in the biosimilar development. At the beginning of a product development, sample sizes of a biosimilar and a reference product may be limited. Thus, a sample size calculation may not be feasible. During the development stage, more batches of reference products may be added a...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2016.1265544

    authors： Dong XC,Weng YT,Tsong Y

    更新日期：2017-01-01 00:00:00

  • An evaluation of increasing sample size based on conditional power.

    abstract：:We evaluate properties of sample size re-estimation (SSR) designs similar to the promising zone design considered by Mehta and Pocock (2011). We evaluate these designs under the assumption of a true effect size of 1.1 down to 0.4 of the protocol-specified effect size by six measures: 1. The probability of a sample siz...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2017.1289943

    authors： Gaffney M,Ware JH

    更新日期：2017-01-01 00:00:00

  • Nonparametric step-down test procedures for finding minimum effective dose.

    abstract：:Nonparametric versions of normal theory step-down multiple-test procedures for inferring minimum effective dose (see Tamhane et al. (1)) were developed and studied by Monte Carlo simulation. Two types of step-down testing procedures were examined. For both procedures, pairwise, linear, or Helmert contrasts of mean ran...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-100101173

    authors： Sidik K,Morris RW

    更新日期：1999-05-01 00:00:00

  • On sample size estimation and re-estimation adjusting for variability in confirmatory trials.

    abstract：:Sample size estimation (SSE) is an important issue in the planning of clinical studies. While larger studies are likely to have sufficient power, it may be unethical to expose more patients than necessary to answer a scientific question. Budget considerations may also cause one to limit the study to an adequate size t...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2015.1092031

    authors： Wu PS,Lin M,Chow SC

    更新日期：2016-01-01 00:00:00

  • Factorial dose-response studies using frequency and magnitude of dose.

    abstract：:In the early stages of traditional drug development, the frequency of dosing (e.g., QD, BID, etc.) is typically determined by the pharmacokinetic properties of a compound. After an appropriate dose frequency is chosen, the magnitude of dose is then evaluated via parallel-group dose-response trials. For some drugs, how...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409608835141

    authors： Hafner KB,Ruberg SJ

    更新日期：1996-07-01 00:00:00

  • An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.

    abstract：:Laboratory data with a lower quantification limit (censored data) are sometimes analyzed by replacing non-quantifiable values with a single value equal to or less than the quantification limit, yielding possibly biased point estimates and variance estimates that are too small. Motivated by a three-period, three-treatm...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2014.920858

    authors： Karon JM,Wiegand RE,van de Wijgert JH,Kilmarx PH

    更新日期：2015-01-01 00:00:00

  • Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.

    abstract：:We study the statistical efficiency for rising-dose designs in the context of first-in-human studies. Specifically, we identify a class of crossover designs that are appealing in terms of both subject safety and statistical efficiency and, for a three-period, two-panel design in such a class, we compare its A-efficien...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2013.792827

    authors： Yan Z,Hosmane B,Locke C

    更新日期：2013-01-01 00:00:00

  • On statistical tests for homogeneity of two bivariate zero-inflated Poisson populations.

    abstract：:The problem of testing treatment difference in the occurrence of a study endpoint in a randomized parallel-group comparative clinical trial with repeated responses under the assumption that the responses follow a bivariate zero-inflated Poisson (ZIP) distribution is considered. Likelihood ratio test for homogeneity of...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2014.919934

    authors： Yuen HK,Chow SC,Tse SK

    更新日期：2015-01-01 00:00:00

  • Dual composite reference standards (dCRS) in molecular diagnostic research: A new approach to reduce bias in the presence of Imperfect reference.

    abstract：:A main challenge in molecular diagnostic research is to accurately evaluate the performance of a new nucleic acid amplification test when the reference standard is imperfect. Several approaches, such as discrepant analysis, composite reference standard (CRS) method, or latent class analysis (LCA), are commonly applied...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2018.1428613

    authors： Tang S,Hemyari P,Canchola JA,Duncan J

    更新日期：2018-01-01 00:00:00

  • Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data.

    abstract：:There is often a need to determine parallelism or linearity between pairs of dose-response data sets for various biological applications. This article describes a technique based on a modification of the well-known extra-sum-of-squares principle of statistical regression. The standard extra-sum-of-squares method uses ...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-200056532

    authors： Gottschalk PG,Dunn JR

    更新日期：2005-01-01 00:00:00

  • Biomarker threshold adaptive designs for survival endpoints.

    abstract：:Due to the importance of precision medicine, it is essential to identify the right patients for the right treatment. Biomarkers, which have been commonly used in clinical research as well as in clinical practice, can facilitate selection of patients with a good response to the treatment. In this paper, we describe a b...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2018.1434191

    authors： Diao G,Dong J,Zeng D,Ke C,Rong A,Ibrahim JG

    更新日期：2018-01-01 00:00:00

  • Estimating treatment effects in clinical crossover trials.

    abstract：:Some current approaches to modeling crossover trials in two treatments are critically reviewed from the perspective of the practical requirements of the drug developer. Particular attention is paid to the AB/BA design, and the inadequacies of the once popular two-stage procedure are discussed in detail. The use of bas...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543409808835233

    authors： Grieve A,Senn S

    更新日期：1998-05-01 00:00:00

  • A bootstrap-based test for establishing noninferiority in clinical trials.

    abstract：:A randomized, active-control clinical trial setting with the objective of testing noninferiority for a continuous response variable is considered. Noninferiority margin is based on the concept of preserving a certain fraction of the active control effect. Noninferiority is established if the ratio of the lower (upper)...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543400600609478

    authors： Chen M,Kianifard F,Dhar SK

    更新日期：2006-05-01 00:00:00

  • Stochastic optimization of adaptive enrichment designs for two subpopulations.

    abstract：:An adaptive enrichment design is a randomized trial that allows enrollment criteria to be modified at interim analyses, based on a preset decision rule. When there is prior uncertainty regarding treatment effect heterogeneity, these trial designs can provide improved power for detecting treatment effects in subpopulat...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2018.1489401

    authors： Fisher A,Rosenblum M,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期：2018-01-01 00:00:00

  • Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

    abstract：:Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intui...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2017.1293075

    authors： Diao G,Zeng D,Ibrahim JG,Rong A,Lee O,Zhang K,Chen Q

    更新日期：2017-01-01 00:00:00

  • A simple and powerful method for the estimation of intervention effects on serological endpoints using paired interval-censored data.

    abstract：:Clinical trials often use a binary "fold increase" endpoint defined according to the ratio of interval-censored measurement at end-of-study to that at baseline. We propose a simple yet principled analytic approach based on the linear mixed-effects model for interval-censored data for the analysis of such paired measur...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2014.919936

    authors： Xu Y,Lam KF,Ooi EE,Wilder-Smith A,Paton NI,Lee LS,Cheung YB

    更新日期：2015-01-01 00:00:00

  • Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.

    abstract：:The small n, Sequential, Multiple Assignment, Randomized Trial (snSMART) is a two-stage clinical trial design for rare diseases motivated by the comparison of three active treatments for isolated skin vasculitis in the ongoing clinical trial ARAMIS (a randomized multicenter study for isolated skin vasculitis, NCT09239...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2020.1815032

    authors： Wei B,Braun TM,Tamura RN,Kidwell K

    更新日期：2020-09-06 00:00:00

  • Designs for testing lack of fit for a nonlinear dose-response curve model.

    abstract：:We would like to estimate the parameters of a dose-response function with the greatest precision as possible. For a two-parameter model, this is equivalent to minimizing the area of the confidence ellipsoid, i.e., a D-optimal design. Previous work on this particular model has included minimal designs. These designs ar...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-100101012

    authors： Lupinacci PJ,Raghavarao D

    更新日期：2000-02-01 00:00:00

  • Mixture-based gatekeeping procedures in adaptive clinical trials.

    abstract：:Clinical trials with data-driven decision rules often pursue multiple clinical objectives such as the evaluation of several endpoints or several doses of an experimental treatment. These complex analysis strategies give rise to "multivariate" multiplicity problems with several components or sources of multiplicity. A ...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2017.1399901

    authors： Kordzakhia G,Dmitrienko A,Ishida E

    更新日期：2018-01-01 00:00:00

  • Statistical considerations in setting product specifications.

    abstract：:According to ICH Q6A (1999), a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. For drug products, specifications usually consist of test methods and acceptance criteria ...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2014.972511

    authors： Dong X,Tsong Y,Shen M

    更新日期：2015-01-01 00:00:00

  • Power approximation for the van Elteren test based on location-scale family of distributions.

    abstract：:The van Elteren test, as a type of stratified Wilcoxon-Mann-Whitney test for comparing two treatments accounting for stratum effects, has been used to replace the analysis of variance when the normality assumption was seriously violated. The sample size estimation methods for the van Elteren test have been proposed an...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543400600762939

    authors： Zhao YD,Qu Y,Rahardja D

    更新日期：2006-01-01 00:00:00

  • Modeling anti-KLH ELISA data using two-stage and mixed effects models in support of immunotoxicological studies.

    abstract：:During preclinical drug development, the immune system is specifically evaluated after prolonged treatment with drug candidates, because the immune system may be an important target system. The response of antibodies against a T-cell-dependent antigen is recommenced by the FDA and EMEA for the evaluation of immunosupp...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：

    authors： Shkedy Z,Straetemans R,Molenberghs G,Desmidt M,Vinken P,Goeminne N,Coussement W,Van Den Poel B,Bijnens L

    更新日期：2005-01-01 00:00:00